Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics is a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna’s pipeline includes KYV-101, a fully human, autologous chimeric antigen receptor (CAR) T-cell therapy with properties well suited for use in B cell-driven autoimmune diseases and KYV-201, a fully human, allogeneic CAR T-cell therapy.  

By offering more than one mechanism for taming autoimmunity, and with patients currently in treatment for multiple indications in the U.S. and Europe, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated.

Vida Ventures

Westlake Village BioPartners

The Argentum Group

CAM Capital

LYFE Capital

RTW Investments

Gilead Sciences

Hudson Bay Capital Management

Insight Partners

Intellia Therapeutics

Bain Capital Life Sciences

Northpond Ventures

GordonMD Global Investments

Kyverna Therapeutics

Ingenui-T uses whole blood from a standard draw, providing a less-invasive alternative to apheresis and offering an improved vein-to-vein experience to patients in need. Our CEO Peter Maag, PhD, and CTO Karen Walker share more about our CAR T #celltherapy, the recent FDA's fast-track clearance of KYV-101 to treat multiple sclerosis, and the priority to establish relationships with CAR T centers with Genetic Engineering & Biotechnology News's Jonathan D. Grinstein, PhD.

#celltherapy #autoimmunediseases

https://lnkd.in/evCJaKDD

Dr. Borie, President, R&D and Dr. Chung, CMO shared the stage with several industry veterans in Silicon Valley this week to discuss the advancements in CAR T-cell therapy and our commitment to patient care. Thank you PMWC - Precision Medicine World Conference for the opportunity to spread the excitement!

#cartcelltherapy #autoimmunediseases #trailblazers

https://www.pmwcintl.com

Ingenui-T is our novel, proprietary method to manufacture chimeric antigen receptor (CAR) T cells from a single whole blood draw, thereby improving patient experience, and their caregivers. Read more about it in the BioRxiv article published today:

https://lnkd.in/eudXgcMx

Apheresis presents challenges with its lengthy and invasive procedure. The high demand for apheresis beds, limited capacity, and resource constraints at collection centers further complicate the process. Kyverna's method addresses these challenges, marking a significant advancement in streamlining the patient experience.

 #cartcelltherapy #autoimmunedisease

https://lnkd.in/eV_XeJWm

As CAR T-cell therapies expanded into the autoimmune space, it was great to be able to present Phacilitate in Miami, FL last week our innovative approaches to change the treatment paradigm.

#cartcelltherapy #autoimmunediseases #Advancedtherapies

 https://lnkd.in/evk77ci7

Kyverna is developing #cartcelltherapy that aims to reset the immune system and provide new hope to individuals suffering from autoimmune conditions, with a focus on #rheumatology and #neurology, by leveraging a patient-centric approach.

Speaking with Xtalks, CEO Peter Maag shares Kyverna's focus on #autoimmunedisease and a vision for the future of autoimmune treatment that could make a tangible difference in patients’ lives.

https://lnkd.in/eXHi5FjB

Our investigational #cartcelltherapy, KYV-101, has received fast track designation from #FDA for use in #multiplesclerosis patients. This marks a significant step forward in our mission to change the paradigm in #autoimmunedisease treatment.

https://lnkd.in/e5hPcJtJ

Our President of R&D, Dominic Borie, M.D., Ph.D., and our CMO, James Chung, are speaking at the #PMWC24 2024 Precision Medicine World Conference in Santa Clara this January 24 and will share more insights on how Kyverna is committed to developing #cartcelltherapy for patients living with #autoimmunedisease. With multiple patients treated for multiple indications at various sites across the world, we believe in shifting the treatment paradigm for serious rheumatological and neuro-immunological autoimmune conditions. 

https://lnkd.in/eb9jkcuz

We're excited to have James Chung, CMO, and Tom Van Blarcom, Senior Vice President and Head of Research, represent Kyverna Therapeutics at Phacilitate.

Join us as James discusses "KYV-101: a Fully Human Autologous CAR T-Cell Therapy for Autoimmune Diseases", and Tom presents on "Kyverna Therapeutics: Transformative Outcomes With Autologous CAR T-Cell Therapy for Autoimmune Diseases.”  

Learn more at https://lnkd.in/evk77ci7

#celltherapy #autoimmunediseases

Our Investigational New Drug application for KYV-101 has received FDA clearance for patients with treatment-refractory progressive #multiplesclerosis, enabling a new therapeutic option that can potentially result in sustained treatment-free remission and alleviate risks of long-term toxicities.

#celltherapy #cart #biopharma

https://lnkd.in/e7UbvFia

Our warmest wishes of the Season to everyone dedicated to changing the paradigm in the treatment of autoimmune diseases.
#cartcelltherapy #autoimmunedisease

	Dec '21	Dec '22	Dec '23
revenue	5.66M -	7.03M 24.20%
cost of revenue		1.05M -	1.71M 62.42%
gross profit	5.66M -	5.97M 5.62%	-1.71M 128.57%
selling and marketing expenses
general and administrative expenses	6.15M -	8.01M 30.20%	12.48M 55.90%
selling general and administrative expenses	6.15M -	8.01M 30.20%	12.48M 55.90%
research and development expenses	25.85M -	28.40M 9.86%	49.92M 75.77%
other expenses	-2K -	-9K 350%	-55K 511.11%
cost and expenses	32.00M -	36.41M 13.77%	62.41M 71.40%
operating expenses	32.00M -	36.41M 13.77%	62.41M 71.40%
interest expense	3K -	65K 2,066.67%	187K 187.69%
ebitda	-25.76M -	-27.78M 7.83%	-58.47M 110.51%
operating income	-26.35M -	-29.38M 11.53%	-62.41M 112.38%
depreciation and amortization	586K -	1.05M 79.35%	1.71M 62.42%
total other income expenses net	-2K -	-9K 350%	-55K 511.11%
income before tax	-26.35M -	-28.89M 9.65%	-60.37M 108.93%
income tax expense	1K -	56K 5,500%	132K 135.71%
net income	-26.35M -	-28.89M 9.65%	-60.37M 108.93%
weighted average shs out	25.80M -	25.80M 0%	40.82M 58.20%
weighted average shs out dil	25.80M -	25.80M 0%	40.82M 58.20%
eps	-1.02 -	-1.12 9.80%	-1.48 32.14%
epsdiluted	-1.02 -	-1.12 9.80%	-1.48 32.14%

KYTX

COM:KYVERNATX

Kyverna TX

Last Close

3.99

22/11 21:00

Market Cap

364.75M

Beta: -

Volume Today

269.18K

Avg: -

Preview